Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.596732/full |
| _version_ | 1818600864510640128 |
|---|---|
| author | Biyong Ren Wei Wang Jing Tan Bo Yuan Guilan Chen Xiaofei Mo Jieqiong Fan Bo Yang Xiaoping Huang |
| author_facet | Biyong Ren Wei Wang Jing Tan Bo Yuan Guilan Chen Xiaofei Mo Jieqiong Fan Bo Yang Xiaoping Huang |
| author_sort | Biyong Ren |
| collection | DOAJ |
| description | Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy. |
| first_indexed | 2024-12-16T12:42:16Z |
| format | Article |
| id | doaj.art-5762ac565cdb4dddb3315c1e84a0b214 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T12:42:16Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-5762ac565cdb4dddb3315c1e84a0b2142022-12-21T22:31:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-06-011110.3389/fonc.2021.596732596732Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case ReportBiyong Ren0Wei Wang1Jing Tan2Bo Yuan3Guilan Chen4Xiaofei Mo5Jieqiong Fan6Bo Yang7Xiaoping Huang8Department of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Gastrointestinal, Thyroid and Vascular Surgery, Chongqing University, Three Gorges Hospital, Chongqing, ChinaDepartment of Oncology, Yunyang County People’s Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, ChinaAngiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy.https://www.frontiersin.org/articles/10.3389/fonc.2021.596732/fullanlotinibangiosarcoma of face and neckcase reportpartial responseprogression-free survival |
| spellingShingle | Biyong Ren Wei Wang Jing Tan Bo Yuan Guilan Chen Xiaofei Mo Jieqiong Fan Bo Yang Xiaoping Huang Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report Frontiers in Oncology anlotinib angiosarcoma of face and neck case report partial response progression-free survival |
| title | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
| title_full | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
| title_fullStr | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
| title_full_unstemmed | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
| title_short | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
| title_sort | efficacy of anlotinib for the treatment of angiosarcoma of the face and neck a case report |
| topic | anlotinib angiosarcoma of face and neck case report partial response progression-free survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.596732/full |
| work_keys_str_mv | AT biyongren efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT weiwang efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT jingtan efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT boyuan efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT guilanchen efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT xiaofeimo efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT jieqiongfan efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT boyang efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT xiaopinghuang efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport |